Artemis Headlands LLC

1. Eli Lilly and Company $13,342,568 114 payments
2. Pfizer Inc. $6,861,255 317 payments
3. Janssen Research & Development, LLC $3,618,094 238 payments
4. Indivior Inc. $2,863,491 348 payments
5. Moderna TX, Inc. $2,378,993 294 payments
6. AbbVie, Inc. $1,450,566 147 payments
7. Roche Diagnostics Operations, Inc. $1,000,829 61 payments
8. Amgen Inc. $818,066 2 payments
9. Boehringer Ingelheim Pharmaceuticals, Inc. $301,147 38 payments
10. Novartis Pharmaceuticals Corporation $295,876 6 payments

1. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $2,747,024 152 payments
2. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $2,101,719 104 payments
3. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $1,945,262 11 payments
4. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $1,707,266 208 payments
5. A Phase 12 Randomized Doubleblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $1,513,298 51 payments
6. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $1,449,899 4 payments
7. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $1,292,547 4 payments
8. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $1,171,393 75 payments
9. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,004,158 5 payments
10. Rd005476 $1,000,829 61 payments

1. Patient care $21,500 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.